Outcomes of daratumumab, pomalidomide, and dexamethasone (DPd) followed by high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) in patients with relapsed/refractory multiple myeloma RRMM
The number of therapeutic options for patients with RRMM has increased significantly. We treated 18 patients with RRMM with DPd as salvage therapy followed by HDCT/ASCT. The ORR after salvage treatment with DPd was 100%. ORR on day 100 post-ASCT was 100%, 67% achieved ≥CR. There was no reported treatment-related mortality on day 100. The 2-year PFS and 2- year OS rate were 83.3% ad 94.4%, respectively
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Al-Ola Abdallah, Ghulam Rehman Mohyuddin, Zahra Mahmoudjafari, Shebli Atrash, Hameem Kawsar, Monia Sigle, Leyla Shune, Joseph McGuirk, Siddhartha Ganguly Tags: Original Study Source Type: research
More News: Chemotherapy | Dexamethasone | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | Transplants